title: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
abstract: OBJECTIVE
  To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.
  
  
  METHODS
  Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.
  
  
  RESULTS
  During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year. The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).
  
  
  CONCLUSIONS
  Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1905 W Taylor St, M/C 648, Chicago, IL 60612, USA. debrgold@yahoo.com
authors.forename: Debra A
authors.initials: DA
authors.lastname: Goldstein
authors.forename: David G
authors.initials: DG
authors.lastname: Godfrey
authors.forename: Anthony
authors.initials: A
authors.lastname: Hall
authors.forename: David G
authors.initials: DG
authors.lastname: Callanan
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Jaffe
authors.forename: P Andrew
authors.initials: PA
authors.lastname: Pearson
authors.forename: Dale W
authors.initials: DW
authors.lastname: Usner
authors.forename: Timothy L
authors.initials: TL
authors.lastname: Comstock
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002648:Child; D004343:Drug Implants; D005260:Female; D005446:Fluocinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000188:drug therapy / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D014130:Trabeculectomy; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy*
chemical_list: D000959:Antihypertensive Agents; D004343:Drug Implants; D005938:Glucocorticoids; D005446:Fluocinolone Acetonide